Cancer treatment and research communications最新文献

{"title":"Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment","authors":"Saki Tanaka ,&nbsp;Motohiro Tamiya ,&nbsp;Satoshi Nishiuma ,&nbsp;Sayaka Nakamura ,&nbsp;Keisuke Nozaki ,&nbsp;Naoko Watanabe ,&nbsp;Chisae Itoh ,&nbsp;Yukio Kadokawa ,&nbsp;Kenji Takeda ,&nbsp;Kozo Takahashi ,&nbsp;Akito Miyazaki ,&nbsp;Takahisa Kawamura ,&nbsp;Kei Kunimasa ,&nbsp;Takako Inoue ,&nbsp;Kazumi Nishino ,&nbsp;Mari Takagi","doi":"10.1016/j.ctarc.2024.100836","DOIUrl":"10.1016/j.ctarc.2024.100836","url":null,"abstract":"<div><h3>Background</h3><p>The most recommended treatment for stage IV EGFR-positive lung cancer is osimertinib monotherapy. The dosage of osimertinib is fixed at 80 mg/day regardless of body surface area (BSA), however some patients withdraw or reduce the dosage due to adverse events (AEs).</p></div><div><h3>Methods</h3><p>We performed a retrospective cohort study of 98 patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who received 80 mg osimertinib as the initial treatment. We investigated the impact of BSA on efficacy and safety of osimertinib.</p></div><div><h3>Results</h3><p>The cut-off value of BSA was estimated using the receiver operating characteristics curve, and was determined to be 1.5 m². There were 44 patients in the BSA &lt; 1.5 group and 54 patients in the BSA ≥ 1.5 group. There was no significant difference in the incidence of AEs (hematologic toxicity of ≥grade 3 or higher, and non-hematologic toxicity of ≥grade 3) between the two groups. However, the incidence of dose reduction due to AEs was significantly higher in the BSA &lt; 1.5 group compared with the BSA ≥ 1.5 group (16 patients vs 5 patients, <em>p</em> = 0.003). The main reasons were fatigue, anorexia, diarrhea, and liver disfunction. Median progression-free survival (PFS) was not significantly different (16.9 months in the BSA &lt; 1.5 group vs 18.1 months in the BSA ≥ 1.5 group, <em>p</em> = 0.869).</p></div><div><h3>Conclusion</h3><p>Differences in BSA affected the optimal dose of osimertinib. However, the PFS with osimertinib treatment was not affected by BSA. Therefore, when using osimertinib as an initial treatment for patients with EGFR-mutant NSCLC, dose reduction to control AEs should be considered, especially in the BSA&lt;1.5 group.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100836"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000480/pdfft?md5=9618c1dc15ff3738502bc6dd4ff016f7&pid=1-s2.0-S2468294224000480-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of neoadjuvant chemotherapy in pregnancy with cervical cancer (IB3)","authors":"Xiaohua Li ,&nbsp;Yu Zhang ,&nbsp;Haiying Wu ,&nbsp;Shaoqiong Li ,&nbsp;Shuxian Ge ,&nbsp;Jian Gao","doi":"10.1016/j.ctarc.2023.100749","DOIUrl":"10.1016/j.ctarc.2023.100749","url":null,"abstract":"<div><p>Compared with the early symptoms of non-pregnancy, the early pregnancy with cervical cancer is often confused with threatened abortion, so it is difficult to diagnose and delay the time of treatment. At present, compared with cervical cancer, there is no clear and standard treatment for cervical cancer in pregnancy. At present, the diagnosis and treatment plan is mainly made according to the pathological examination, staging, fetal development (whether there is abnormality on ultrasound and whether the chromosome karyotype is normal or not) and the pregnant women and their family members’ pregnancy wishes. A case of pregnancy complicated with cervical cancer who was terminated by planned cesarean section after neoadjuvant chemotherapy (NACT) with irregular vaginal bleeding as the first symptom was analyzed retrospectively.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"38 ","pages":"Article 100749"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223000710/pdfft?md5=f9b40e7d3b275a37f39006f987756fb8&pid=1-s2.0-S2468294223000710-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48065102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study","authors":"Luiz Ricardo Soldi ,&nbsp;Diogo Henrique Rabelo ,&nbsp;Paulo Henrique Rosa da Silva ,&nbsp;Victor Luigi Costa Silva ,&nbsp;Marcelo José Barbosa Silva","doi":"10.1016/j.ctarc.2024.100790","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100790","url":null,"abstract":"<div><h3>Purpose</h3><p>Hodgkin's lymphoma is currently treated with a chemotherapy protocol consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine. Due to Brazil facing a bleomycin shortage in 2017, and this drug's high toxicity, this retrospective study evaluates the effect that the absence of bleomycin had on treatment response and overall survival of Hodgkin's lymphoma patients.</p></div><div><h3>Methods</h3><p>The medical records of 126 HL patients treated between 2007 and 2021 were reviewed and their data collected, followed by grouping into ABVD and AVD groups according to bleomycin use. Data concerning the patient's characteristics, cancer type, and treatment plan were analyzed with proportion tests, Kaplan-Meier curves. univariate Cox regression, and χ² tests.</p></div><div><h3>Results</h3><p>No discernible differences were found in this study between the overall survival and recurrence rate of patients treated with bleomycin compared to those without. Additionally, there was an increased risk of death in each subsequent cycle of chemotherapy of the complete ABVD protocol, demonstrating a risk of toxicity. Among the variables analyzed, hypertension and the presence of B symptoms were also associated with an increased risk of death, while the use of radiotherapy significantly improved survival.</p></div><div><h3>Conclusion</h3><p>The results of this study suggest that bleomycin did not impact the outcome of Hodgkin's lymphoma treatment. Moreover, the increased risk of death associated with its toxicity during each cycle of treatment raises concerns about its role as an essential component of the gold standard for Hodgkin's lymphoma treatment. Therefore, further research and consideration are needed to reassess the use of bleomycin in Hodgkin's lymphoma treatment protocols.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"38 ","pages":"Article 100790"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000029/pdfft?md5=83cf927e29ef9f9a348333ad2ed4c115&pid=1-s2.0-S2468294224000029-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139494074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal cancer survival and prognostic factors in Iranian population: A retrospective cohort study","authors":"Seyed Kazem Mirinezhad ,&nbsp;Mostafa Akbarzadeh-Khiavi ,&nbsp;Farshad Seyednejad ,&nbsp;Mohammad Hossein Somi","doi":"10.1016/j.ctarc.2024.100810","DOIUrl":"10.1016/j.ctarc.2024.100810","url":null,"abstract":"<div><h3>Background</h3><p>Rectal cancer (RC) poses a significant global health challenge, causing substantial morbidity and mortality. This study aims to investigate the survival rates of RC patients and identify the factors that influence their survival. The study considers demographic characteristics, tumor features, and treatment received as the factors under consideration.</p></div><div><h3>Methods</h3><p>A retrospective analysis was conducted on the medical records of 593 RC patients. Data were collected through a comprehensive review of medical records and conducting telephone interviews. Survival rates were estimated using the life table method, and subgroup comparisons were performed using the log-rank test. Cox regression analysis was utilized to assess the independent associations between RC survival time and various covariates.</p></div><div><h3>Results</h3><p>The study cohort comprised 593 RC patients, with a predominantly male representation. The mean age at diagnosis was 58.18 years, and the majority of patients (78.6 %) underwent surgical interventions. The median age at symptom onset and diagnosis were 58 and 59 years, respectively. Survival rates at 1st, 3rd, 5th, and 10th years were estimated to be 85 %, 59 %, 47 %, and 36 %, respectively. Statistical analysis revealed several significant prognostic factors, including age, education, symptoms, and cancer stage. In the multivariate Cox proportional-hazards analysis, advanced regional stage (HR = 1.54, 95 % CI, 1.13–2.08), presence of metastasis (HR = 3.73, 95 % CI, 2.49–5.58), and age over 70 (HR = 1.65) were associated with a higher risk of mortality.</p></div><div><h3>Conclusion</h3><p>Given the alarming prognosis of RC observed in the study area and the significant delay between symptom onset and diagnosis, it is crucial to address this issue and potentially improve the survival rates of RC patients.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100810"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000224/pdfft?md5=f3cd7f224a762464d244f0a233e484b3&pid=1-s2.0-S2468294224000224-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes of physicians and patients toward immediate and intraoperative chemotherapy treatment in colon cancer","authors":"Mehraneh D. Jafari ,&nbsp;Andrea Mesiti ,&nbsp;Julianna Brouwer ,&nbsp;Chelsea McKinney ,&nbsp;Lari B. Wenzel ,&nbsp;Alessio Pigazzi ,&nbsp;Jason A. Zell","doi":"10.1016/j.ctarc.2024.100798","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100798","url":null,"abstract":"<div><h3>Introduction</h3><p>We have shown in a Phase I trial that immediate adjuvant chemotherapy (IAC) during surgical resection and immediately postoperative is safe and feasible in patients with colon cancer (CC). IAC avoids delays in adjuvant treatment and has the potential to improve survival and quality of life. We aim to determine patients and providers attitudes toward this novel multidisciplinary treatment approach.</p></div><div><h3>Methods</h3><p>Two web-based surveys were administered to newly diagnosed CC patients, survivors, surgeons and oncologists. Surveys assessed treatment preferences and perceived barriers to IAC. Chi-square tests were conducted to compare differences between patients’ and providers’ responses.</p></div><div><h3>Results</h3><p>Responses were collected from 35 patients and 40 providers. Patients were more willing to: (1) proceed with IAC to finish treatment earlier thus possibly improving quality of life (<em>p</em> = 0.001); (2) proceed with IAC despite potential side effects (<em>p</em> &lt; 0.001); and (3) proceed with a dose of intraoperative chemotherapy even if on final pathology, may not have been needed (<em>p</em> = 0.002). Patients were more likely to indicate no barriers to collaborative care (<em>p</em> = 0.001) while providers were more likely to cite that it is time consuming, thus a barrier to participation (<em>p</em> = 0.001), has scheduling challenges (<em>p</em> = 0.001), and physicians are not available to participate (<em>p</em> = 0.003).</p></div><div><h3>Conclusions</h3><p>We observed a discordance between what providers and patients value in perioperative and adjuvant CC treatment. Patients are willing to accept IAC despite potential side effects and without survival benefit, highlighting the importance of understanding patient preference.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"39 ","pages":"Article 100798"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000108/pdfft?md5=8ca70afb2272b954ac368cf708081f3c&pid=1-s2.0-S2468294224000108-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer","authors":"Maria Ignez Freitas Melro Braghiroli ,&nbsp;Daniel Santos Rocha Sobral Filho ,&nbsp;Juliana Goes Martins Fagundes ,&nbsp;Elizabeth Zambrano Mendoza ,&nbsp;Maria Fernanda Batistuzzo Vicentini Neffa ,&nbsp;Karla Souza Campos ,&nbsp;Leonardo Gomes da Fonseca ,&nbsp;Renata Colombo Bonadio ,&nbsp;Aley Talans ,&nbsp;Oddone Freitas Melro Braghiroli ,&nbsp;Maria Cecília Mathias-Machado ,&nbsp;Jorge Sabbaga ,&nbsp;Camila Motta Venchiarutti Moniz ,&nbsp;Paulo Marcelo Gehm Hoff","doi":"10.1016/j.ctarc.2025.100867","DOIUrl":"10.1016/j.ctarc.2025.100867","url":null,"abstract":"<div><h3>Purpose</h3><div>There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment for metastatic colorectal cancer.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort of metastatic colorectal cancer patients who progressed to irinotecan monotherapy and were exposed to an anti-EGFR antibody as a third line of treatment. This study was conducted at a single cancer center in Brazil. The primary outcome was overall survival. The secondary outcomes were objective response rate, stratified by primary tumor sidedness, progression-free survival, and toxicity.</div></div><div><h3>Results</h3><div>This analysis included 412 patients who had progressed on irinotecan and were KRAS wild-type. One hundred eighty-two received Irinotecan plus Cetuximab (I + C group) and 230 Irinotecan plus Panitumumab (<em>I</em> + <em>P</em> group). There was no significant difference in median overall survival between treatment groups (9.1 months [I + C] vs 10.1 months [<em>I</em> + <em>P</em>]; <em>p</em> = 0.76). There was also no difference in progression-free survival (3.63 months [I + C] vs 3.73 months [<em>I</em> + <em>P</em>]; <em>p</em> = 0.19) and objective response rate (23.0 % [I + C] vs 22.3 % [<em>I</em> + <em>P</em>]; <em>p</em> = 0.97). Patients with right-sided tumors had worse overall survival than left-sided (6.2 months vs 10.1 months; <em>p</em> = 0.003) but presented a better objective response rate with panitumumab (8.3 % [<em>I</em> + <em>P</em>] vs 3.3 % [I + C]). There were more infusion reactions with cetuximab.</div></div><div><h3>Conclusions</h3><div>Panitumumab and cetuximab have similar activity when combined with irinotecan as treatment for patients with disease progression with an irinotecan regimen, potentially rescuing the irinotecan activity.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100867"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations","authors":"Jason C.S. Ho,&nbsp;K.M. Cheung","doi":"10.1016/j.ctarc.2025.100863","DOIUrl":"10.1016/j.ctarc.2025.100863","url":null,"abstract":"<div><div>Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the 123 patients who underwent definitive chemoradiation, 33 had common driver mutations, including EGFR mutations, ALK rearrangements, ROS1 rearrangements, and RET fusions. The addition of durvalumab did not improve real-world recurrence-free survival (rwRFS) in patients with these mutations (hazard ratio [HR] 0.852, 95 % confidence interval [CI] 0.394 – 1.843, <em>p</em>= 0.683). In contrast, rwRFS significantly improved for patients without common mutations (HR 0.342, 95 % CI 0.203 – 0.577, <em>p</em>&lt; 0.001). These findings suggest that consolidation durvalumab may not be beneficial for patients with common driver mutations, underscoring the need for personalized treatment strategies in this population.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100863"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging role of blood-based biomarkers in early detection of colorectal cancer: A systematic review","authors":"Faris Shweikeh ,&nbsp;Yuhao Zeng ,&nbsp;Abdur Rahman Jabir ,&nbsp;Erica Whittenberger ,&nbsp;Saurav P. Kadatane ,&nbsp;Yuting Huang ,&nbsp;Mohamad Mouchli ,&nbsp;Dani Ran Castillo","doi":"10.1016/j.ctarc.2025.100872","DOIUrl":"10.1016/j.ctarc.2025.100872","url":null,"abstract":"<div><h3>Background</h3><div>Colorectal cancer (CRC), the third most commonly diagnosed and second most lethal cancer worldwide, necessitates efficient early detection strategies to improve patient outcomes. This review evaluates the promise of novel blood-based biomarkers for early detection of CRC.</div></div><div><h3>Methods</h3><div>A systematic review, registered with PROSPERO (CRD42024513770) and adhering to PRISMA guidelines, was conducted across multiple databases from January 1st, 2020 to December 31st, 2022. The comprehensive search strategy centered on sensitivity, specificity, and AUC-ROC of multiple types of molecular blood biomarkers.</div></div><div><h3>Results</h3><div>Of total of 142 included articles, 59 were on protein, 58 on RNA, and 21 on DNA. The investigation into DNA biomarkers revealed that cfDNA and ctDNA carry significant potential for early CRC diagnosis. For instance, methylation patterns in genes such as <em>MYO1-</em>G and <em>NDRG4</em> exhibited high diagnostic accuracies with AUCs reaching up to 0.996. RNA biomarkers like miRNAs and circRNAs also showed promising results, with circ_0011536 achieving AUCs of 0.982. Protein biomarkers, contrasted with established cancer markers, unveiled notable candidates like Irisin and ANXA2, with AUCs surpassing 0.96. The review highlights several individual markers and panels with the potential to improve upon existing CRC screening tests.</div></div><div><h3>Conclusions</h3><div>Despite the promise shown by the novel biomarkers, challenges persist, including small sample sizes, potential selection biases, and a lack of comprehensive cost-effectiveness analysis. Future research should focus on large-scale, multicenter, prospective studies across diverse populations. The findings advocate for an integrated biomarker approach, potentially revolutionizing CRC screening and aligning it with clinical realities through rigorous validation.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100872"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Her-2/neu value in papillary thyroid carcinoma and its relation to histopathological prognostic findings","authors":"Amin Azarnoosh,&nbsp;Elahe Farmani,&nbsp;Farzaneh Niki Boroujeni,&nbsp;Elham Nazar","doi":"10.1016/j.ctarc.2024.100840","DOIUrl":"10.1016/j.ctarc.2024.100840","url":null,"abstract":"<div><h3>Introduction</h3><p>Thyroid cancer is an important endocrine malignancy worldwide, including papillary carcinoma, which is responsible for more than 90 % of thyroid malignancies. Human epidermal growth factor receptor 2 (Her-2/neu) overexpression plays a significant act in the development, progression, and invasion of various tumors through effects on the cell cycle, angiogenesis, cell movement, and apoptosis.</p></div><div><h3>Objective and methods</h3><p>The study was conducted as a cross-sectional study, using tissue samples from 53 patients who underwent lobectomy or total thyroidectomy between 2020 and 2022. For histopathological examination and to determine the pathological features of the tumor, tumor specimens were stained for immunohistochemistry using a monoclonal antibody against Her-2/neu.</p></div><div><h3>Results</h3><p>In this study, Her-2/neu was expressed in 13.2 % of PTC patients and not expressed in normal thyroid tissue. No significant relationship was established between Her-2/neu expression and tumor histological subtype, as well as tumor size, sex, or tumor focality. Furthermore, there was no significant association between Her-2/neu expression and vascular invasion or extrathyroidal extension of the tumor.</p></div><div><h3>Conclusion</h3><p>No significant Her-2/neu expression was observed in the malignant thyroid tissue. These findings raise questions about the value of Her-2/neu as a potential prognostic factor or target of a specific anticancer treatment for thyroid cancer.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"41 ","pages":"Article 100840"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000522/pdfft?md5=14dda4d5ee75ff35aa2e7d01ed9a6084&pid=1-s2.0-S2468294224000522-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142096669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion–mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study","authors":"Nicolas Girard ,&nbsp;Keunchil Park ,&nbsp;Se-Hoon Lee ,&nbsp;Santiago Viteri ,&nbsp;Claudio A. Schioppa ,&nbsp;Joris Diels ,&nbsp;Mustafa Oguz ,&nbsp;Bernardo H. Rodrigues ,&nbsp;Nora Rahhali ,&nbsp;Jan Sermon ,&nbsp;Francesca Ghilotti ,&nbsp;Tracy Li ,&nbsp;Meena Thayu ,&nbsp;Roland E. Knoblauch ,&nbsp;Parthiv Mahadevia ,&nbsp;Byoung Chul Cho","doi":"10.1016/j.ctarc.2024.100832","DOIUrl":"10.1016/j.ctarc.2024.100832","url":null,"abstract":"<div><h3>Background</h3><p>Amivantamab, an EGFR-MET bispecific antibody, is the first approved targeted therapy for patients with <em>EGFR</em> Ex20ins NSCLC after prior platinum-based chemotherapy—a population with historically poor outcomes before amivantamab approval. As antitumor activity in single-arm studies typically focuses on responders, the evaluation of outcomes in patients with stable disease (SD) as best response is of clinical interest.</p></div><div><h3>Patients and methods</h3><p>Among 114 patients with post-platinum <em>EGFR</em> Ex20ins NSCLC in CHRYSALIS (NCT02609776; data cutoff: March 30, 2021), response was assessed by blinded independent central review via RECIST v1.1. Patients alive and receiving therapy at 12 weeks were grouped by response at this landmark: partial or complete response (PR+), SD, or progressive disease (PD). Progression-free survival (PFS) and overall survival (OS) by response cohort were determined using the Kaplan-Meier method; hazard ratios (HRs) and 95% confidence intervals (CIs) between response cohorts were calculated using Cox proportional hazards regression.</p></div><div><h3>Results</h3><p>Among patients alive and receiving therapy at 12 weeks (n=107), 42 (39%) had PR+, 52 (49%) had SD, and 13 (12%) had PD. Among patients with PR+ and SD, median PFS was 12.2 and 7.0 months, respectively. A corresponding improvement in OS was observed in patients achieving PR+ (median: not reached; HR vs PD=0.21 [95% CI: 0.08–0.54]) and SD (median: 23.0 months; HR vs PD=0.33 [95% CI: 0.14–0.77]), relative to those with PD (median: 14.0 months).</p></div><div><h3>Conclusion</h3><p>SD was observed in 49% of patients receiving amivantamab, with corresponding increases in OS that dramatically improved the prognoses of this patient population.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100832"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000443/pdfft?md5=5f37518a464c8ffe36c0b6772e0ef5c3&pid=1-s2.0-S2468294224000443-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141703919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}